Drug Profile
HD 003
Alternative Names: 5-Hydroxy-1-methylhydantoin; HD-003; NZ-419Latest Information Update: 06 Sep 2017
Price :
$50
*
At a glance
- Originator Nippon Zoki
- Developer Hyundai Pharmaceutical; Nippon Zoki
- Class Hydantoins; Small molecules; Urologics
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal failure
Most Recent Events
- 06 Sep 2017 Discontinued - Phase-II for Renal failure in South Korea (PO)
- 05 Oct 2012 Discontinued - Phase-II for Renal failure in Japan (PO)
- 26 Apr 2007 Phase II development is ongoing